[(223)Ra] RaCl(2) nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era

The treatment of bone metastatsis as primary bone cancer itself is still a challenge. The use od radium dichloride ([(223)Ra] RaCl(2)) has emerged in the last few years as one of the best treatment choice for bone cancer, with especial focus in bone metastasis. The alpha-emitter radiopharmaceutical has showed potent and efficient results in several clinical trials. In this study we have formulated radium dichloride ([(223)Ra] RaCl(2)) nanomicelles in order to evaluate and compare with pure radium dichloride ([(223)Ra] RaCl(2)). The results showed that nanomicelles at the same dose had a superior effect (20% higher efficient) when compared with pure radium dichloride ([(223)Ra] RaCl(2)). The results corroborated the effectiveness of the nanosystem validating the application of nanotechnology in alpha-radiotherapy with radium dichloride ([(223)Ra] RaCl(2)).